Mission
Adrenocortical cancer (ACC), is a rare human cancer, with an incidence of 0.7-2 per million per year. From a patient point of view it represents an unmet therapeutic need; in a significant proportion of patients cure cannot be attained. The comparative infrequent prevalence of ACC has created a particular hurdle in advancing research and improving outcome for patients. The low incidence has therefore also stimulated international cooperation. The Nefkens Adrenal Cancer Foundation has been established to support research in adrenocortical cancer (ACC) with clinical impact. It is our mission to support innovative research with the ultimate objective to break grounds in the outcome, care and cure of patients with ACC.